Press releases
The Swedish Economic Crime Authority terminates the investigation of Oncopeptide's Chief Scientific Officer Jakob Lindberg
May 30, 2023
Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, has been informe...
Bulletin from the Annual General Meeting in Oncopeptides AB (publ)
May 25, 2023
Stockholm, Sweden – The Annual General Meeting in Oncopeptides AB (publ) (ONCO) was held on Thursday, 25 May 2023. At the Annual General Meeting, the following principal resolutions were passed
Correction: Oncopeptides presents new data at the European Haematology Association meeting
May 12, 2023
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announces t...
Oncopeptides presents new data at the European Haematology Association meeting
May 11, 2023
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announces t...
Oncopeptides publishes Q1 report 2023
May 4, 2023
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today publishes t...
Oncopeptides issues warrants to utilize the first loan tranche from EIB
May 3, 2023
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat haematological diseases, today announced ...
Invitation to presentation of the Q1 report 2023
May 2, 2023
Oncopeptides AB (publ) a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, will publish the report for the first quart...
Oncopeptides publishes the 2022 Annual Report
April 25, 2023
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announces t...
Annual General Meeting in Oncopeptides AB (publ)
April 21, 2023
The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Annua...
Oncopeptides presents new scientific data at European Myeloma Network Meeting
April 20, 2023
Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announced ...
Oncopeptides receives a research grant from Sweden´s Innovation Agency to explore the PDC platform in solid tumors
March 28, 2023
Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development and commercialization of therapies for difficult-to-treat hematological diseases, today announced t...
Oncopeptides CSO released from custody
March 10, 2023
Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on the commercialization, research and development of therapies for difficult-to-treat hematological diseases, has been info...
Oncopeptides CSO investigated for violation of the Market Abuse Act
March 8, 2023
Oncopeptides AB (publ), has been informed by the Swedish Economic Crime Authority that the CSO Jakob Lindberg has been arrested for a suspected violation of the Market Abuse Act (Sw. lag om straff för...
Oncopeptides publishes year-end report 2022
February 16, 2023
Oncopeptides AB (publ), a biotech company focused on research, development and commercialization of therapies for difficult-to-treat hematological diseases, has today published the year-end report 202...
Invitation to presentation of the year-end report 2022
February 9, 2023
Oncopeptides AB (publ) a biotech company focused on the commercialization, research and development of therapies for difficult-to-treat hematological diseases, will publish the report for the fourth q...
Oncopeptides Chief Financial Officer Holger Lembrer takes office today
January 18, 2023
STOCKHOLM - January 18, 2023 - Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on commercialization, research, and development of therapies for difficult-to-treat hematolog...
Oncopeptides appoints Holger Lembrer as Chief Financial Officer
January 11, 2023
STOCKHOLM — January 11, 2023 — Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today...
Monica Shaw appointed CEO of Oncopeptides – Jakob Lindberg assumes position as Chief Scientific Officer
January 4, 2023
STOCKHOLM — January 4, 2023 — Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today ...